Aptamer Group is an AIM listed, leading provider of aptamer selection services and developer of aptamer-based reagents for use in research, bioprocessing, diagnostic, and therapeutic applications. Headquartered in York, UK, the Company partners globally to deliver aptamer-based solutions that drive discovery and development across the life sciences.
The Group has developed the proprietary Optimer® platform technology that drives three distinct businesses: Aptamer Solutions, Aptamer Diagnostics and Aptamer Therapeutics. Through the use of its Optimer platform the Company aims to enable new opportunities, including discovery and development partnerships for improved biologic drugs, and new applications, such as novel assays and targets, to accelerate discovery and improve current standard processes.
Firm Placing, Conditional Placing and Subscription
The Fundraise is being conducted in two tranches and comprises:
- A firm placing of 10,318,390 New Ordinary Shares (the “Firm Placing Shares”) at the Issue Price, to raise approximately £0.1 million, which is not conditional on Shareholder approval and which instead will utilise the Company’s existing authorities to allot shares and disapply pre-emption rights granted at the Company’s Annual General Meeting in December (the “Firm Placing”); and
- A conditional placing of 339,281,610 New Ordinary Shares (the “Conditional Placing Shares”) at the Issue Price to raise approximately £3.4 million (before expenses) (the “Conditional Placing Shares”) and a conditional subscription for 10,400,000 New Ordinary Shares (the “Subscription Shares”) to raise approximately £0.1 million (before expenses), each of which will require Shareholder approval at the General Meeting.
The Issue Price represents a discount of 78.95 per cent. to the closing price per Ordinary Share of 4.75 pence at close of business on 28 July 2023, being the last practicable date prior to the announcement of the Fundraise. The New Ordinary Shares to be issued will represent approximately 84.26 per cent. of the Enlarged Issued Share Capital.
First Admission of the Firm Placing Shares is expected to become effective and dealings are expected to commence at 8.00 a.m. on 4 August 2023.
Subject to the passing of the Resolutions at the General Meeting, Second Admission of the Conditional Placing Shares and the Subscription Shares is expected to become effective and dealings are expected to commence at 8.00 a.m. on 21 August 2023.
For further information, click here.
Having helped Aptamer when they floated on AIM in December 2021, the Pervan shareholder communications team was delighted to work with Squire Patton Boggs who acted as legal advisor to Aptamer on the on the production of the documentation which was successfully completed and posted on 31st July 2023.
Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.